Research Study

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of IXAZOMIB (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Principal Investigator 
Kevin Song


Body Locations and Systems 
Disorders and Conditions 
Multiple Myeloma 
Closed for Recruitment
Study Start/End 
Sep 12, 2011 to Dec 31, 2018
Vancouver General Hospital
Jennifer Normandeau, Research Nurse
604-875-4111 ext.67227
Purpose of Study 

This will be a phase 1/2, multicenter, 2-arm, open-label study using the oral formulation of IXAZOMIB when added to standard melphalan and prednisone (MP) treatment. Both phases of the study will include patients who have newly diagnosed multiple myeloma and are ineligible for high-dose therapy plus stem cell transplantation because of age (≥65 years of age) or coexisting conditions and for whom standard MP treatment is indicated.


Visit for more information.


Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.